Does ketokonazole on its own improve androgenetic alopecia? Ketoconazole 3/18/2026
Ketoconazole can slightly improve hair density and is best used as an adjunct to treatments like finasteride and minoxidil. It helps with scalp health but won't stop androgenetic alopecia on its own.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Been using Dutasteride, Ru58841, Minoxidil, and Ketaconozole for years. Still can't stop shed, recession or loss of density.
Despite using dutasteride, RU58841, minoxidil, and ketoconazole for years, the user continues to experience severe hair loss and thinning. They seek advice after multiple dermatologists confirmed androgenetic alopecia (AGA) but offered no effective solutions.
community 6 months of 1 mg of oral finasteride a day and 2ml of topical minoxidil 5%
A user shared impressive hair regrowth results after six months of using 1 mg oral finasteride daily, 2 ml topical minoxidil 5%, ketoconazole shampoo, and vitamin D and iron supplements. The user reported no side effects and attributed the success to a combination of treatments for androgenetic alopecia and iron deficiency.
community Good recovery to diffuse thinning
A 25-year-old male with androgenetic alopecia experienced improved hair condition after using finasteride, oral minoxidil, and dutasteride, but later faced diffuse thinning and texture deterioration after a shedding phase. Others suggest patience, continued treatment, and using ketoconazole shampoo, with some sharing similar experiences of post-shed thinning.
community 31M. Just diagnosed with androgenic alopecia. Fears of min.
A 31-year-old man with androgenic alopecia is considering treatments like finasteride, minoxidil, and ketoconazole shampoo but is worried about finasteride's side effects. Users recommend starting with finasteride or dutasteride for DHT blocking, suggesting topical solutions to reduce side effects.
community AGA evaluation and first steps - BEGINNER MEGAPOST
The conversation discusses androgenic alopecia (AGA) and its treatments, focusing on finasteride, minoxidil, and ketoconazole shampoo. Finasteride is recommended as essential for preventing further hair loss.
Related Research
6 / 6 results
research Minoxidil: a comprehensive review
This study reported that while topical minoxidil exhibits hair regrowth in androgenetic alopecia, oral minoxidil 5 mg/day was more effective than topical forms after six months, with low doses also potentially effective for women and other hair loss types.
research Efficacy and Safety of Oral Minoxidil 5 mg Once Daily in the Treatment of Male Patients with Androgenetic Alopecia: An Open-Label and Global Photographic Assessment
This study found that low-dose oral minoxidil 5 mg daily significantly increased hair growth in men with androgenetic alopecia over 24 weeks, with increased hair count and vertex area improvement, though most experienced hypertrichosis and some had pedal edema.
research Inhibition of Rab27a and Rab27b Has Opposite Effects on the Regulation of Hair Cycle and Hair Growth
This study found that Rab27a and Rab27b play opposite roles in hair growth, with Rab27a knockdown suppressing and Rab27b knockdown promoting hair growth in models.
research Overactive bladder in men
This chapter discusses the increasing prevalence of overactive bladder in aging men, examining potential causes and treatment options, without reporting new clinical results.
research Extracellular vesicles derived from MSCs activates dermal papilla cell in vitro and promotes hair follicle conversion from telogen to anagen in mice
This study found that treatment with mesenchymal stem cell extracellular vesicles enhanced hair growth in mice and stimulated dermal papilla cell activity and growth factor production in vitro.
research Treatment of frontal fibrosing alopecia and lichen planopilaris: a systematic review
This study reported that while no effective treatment exists for frontal fibrosing alopecia, oral 5-alpha-reductase inhibitors showed the most promise, inducing a good clinical response in 45% of patients.